论文部分内容阅读
尼索地平(简称NIS)是一种双氢吡啶类钙拮抗剂,与硝苯啶相比,本品具有强力冠脉和体循环血管扩张作用,而几乎无负性肌力作用,在使用扩张冠脉血管剂量时,对体循环动脉无明显作用。本品的这种选择性扩血管作用在治疗冠心病中具有重要意义。本文旨在采用随机、双盲、交叉、安慰剂对照试验评价了NIS和普萘洛尔(PRO)单用及两者联用对慢性稳定型劳力性心绞痛的急性疗效。 14例慢性稳定型心绞痛病人,均有显著的冠脉狭窄,以往均未服过NIS或PRO。在2周单盲安慰剂试验期结束后,所有病人均
Nisoldipine (NIS) is a dihydropyridine calcium antagonist, compared with nifedipine, this product has a strong coronary and systemic vascular dilatation, and almost no negative inotropic effect, the use of dilated crown Vascular dose, the body circulation artery no significant effect. This product is the role of this selective vasodilatation in the treatment of coronary heart disease is of great significance. This study aimed to evaluate the acute effects of NIS and propranolol (PRO) alone and in combination on chronic stable angina pectoris using a randomized, double-blind, crossover, placebo-controlled trial. Of the 14 patients with chronic stable angina who had significant coronary stenosis, none of them had previously received NIS or PRO. After 2 weeks of single-blind placebo trial, all patients were